Zymeworks (ZYME) Stock Price, News & Analysis

Company Overview

Zymeworks Inc. is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. The company uses its proprietary Azymetric and EFECT antibody-engineering platforms to design multifunctional biotherapeutics, including bispecific antibodies and antibody-drug conjugates intended to address complex disease biology.

Zymeworks’ leading product is zanidatamab, a bispecific antibody targeting HER2. In the United States, zanidatamab is marketed as Ziiたhera for previously treated, unresectable or metastatic HER2-positive biliary tract cancer. Jazz Pharmaceuticals is responsible for commercialization under a global licensing and collaboration agreement, while Zymeworks continues to receive development-related benefits and advances additional applications of the therapy.

Founded in 2003, Zymeworks is headquartered in Vancouver, British Columbia, and maintains operations in the United States. In addition to zanidatamab, the company is developing a pipeline of investigational antibody-based therapies for oncology and other therapeutic areas. Kenneth Galbraith serves as chief executive officer, having previously held senior commercial and business-development roles in the biopharmaceutical industry.

Key Stats

• Today's Range: $26.01 to $26.56
• 50-Day Range: $21.81 to $31.05
• 52-Week Range: $16.00 to $31.34
• Volume: 24,396 shs
• Average Volume: 691,115 shs
• Market Capitalization: $1.85 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $40.45
• Consensus Rating: Moderate Buy

Zymeworks Stock Analysis - MarketRank™

Zymeworks scored higher than 52% of companies evaluated by MarketBeat, and ranked 496th out of 891 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Zymeworks has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on no strong buy ratings, 11 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Zymeworks has a consensus price target of $40.45, representing about 54.2% upside from its current price of $26.23.

Amount of Analyst Coverage

Zymeworks has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: -63.04%

Earnings Growth

Earnings for Zymeworks are expected to decrease by -63.04% in the coming year, from $1.38 to $0.51 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Zymeworks is -12.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Zymeworks is -12.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Zymeworks has a P/B Ratio of 7.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.47% of the float of Zymeworks has been sold short.

Short Interest Ratio / Days to Cover

Zymeworks has a short interest ratio ("days to cover") of 7.97.

Change versus previous month

Short interest in Zymeworks has recently increased by 4.53%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Zymeworks does not currently pay a dividend.

Dividend Growth

Zymeworks does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.33

News Sentiment

Zymeworks has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for Zymeworks this week, compared to 6 articles on an average week.

Search Interest

Only 1 people have searched for ZYME on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

5 people have added Zymeworks to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Zymeworks insiders have not sold or bought any company stock.

Percentage Held by Insiders

33.51% of the stock of Zymeworks is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

92.89% of the stock of Zymeworks is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/07/2026
• Today: 10/01/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ZYME
• Previous Symbol: NASDAQ:ZYME
• CIK: 1937653
• Web: zymeworks.com
• Phone: (302) 274-8744
• Fax: 604-737-7077
• Employees: 264
• Year Founded: 2003

Price Target and Rating

• Average Price Target for Zymeworks: $40.45
• High Price Target: $58.00
• Low Price Target: $32.00
• Potential Upside/Downside: +55.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.77
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 18.91
• P/E Growth: N/A
• Net Income: -$81.13 million
• Net Margins: -405.31%
• Pretax Margin: -407.76%
• Return on Equity: -72.30%
• Return on Assets: -37.18%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.32
• Quick Ratio: 6.32

Sales & Book Value

• Annual Sales: $105.96 million
• Price / Sales: 17.48
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.59 per share
• Price / Book: 7.27

Miscellaneous

• Outstanding Shares: 70,960,000
• Free Float: 47,181,000
• Market Cap: $1.85 billion
• Optionable: N/A
• Beta: 1.19